Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance

24 Jun 2021

Abstract excerpt

Our study details the stepwise evolution of gilteritinib resistance in FLT3-mutated acute myeloid leukemia (AML). Early resistance is mediated by the bone marrow microenvironment, which protects residual leukemia cells. Over time, leukemia cells evolve intrinsic mechanisms of resistance, or late resistance. We mechanistically define both early and late resistance by integrating whole-exome sequencing,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34171263
DOI: 10.1016/j.ccell.2021.06.003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistancePMID 34171263Read ↗

Stepwise evolution of therapy resistance in AML.Semantic proximity Read ↗

BMX kinase mediates gilteritinib resistance in FLT3-mutated AML through microenvironmental factors.Semantic proximity Read ↗

Precision medicine in AML: overcoming resistance.Semantic proximity Read ↗

Uncovering pre-sensitizing agents to FLT3 inhibitors in acute myeloid leukemia with ReSisTrace lineage tracingSemantic proximity Read ↗

A noncanonical FLT3 gatekeeper mutation disrupts gilteritinib binding and confers resistanceSemantic proximity Read ↗

Multi-omics dissection of tumor microenvironment-mediated drug resistance: mechanisms and therapeutic reprogrammingSemantic proximity Read ↗

Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin.Semantic proximity Read ↗

RAS pathway activation drives clonal selection and monocytic differentiation in FLT3 and BCL2 inhibitor resistanceSemantic proximity Read ↗

Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanismsSemantic proximity Read ↗

LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML.Semantic proximity Read ↗

Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML.Semantic proximity Read ↗

A Role for the Bone Marrow Microenvironment in Drug Resistance of Acute Myeloid LeukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.